MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide Transcript
MBX Biosciences Highlights Sustained Calcium Control In Rare Disease
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics Portfolio Transcript
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights
Microbix Schedules Release of Results for Q2 Fiscal 2026
MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award
3 Overlooked Stocks Set to Soar in 2026
Microbix Product Results Being Presented at 2026 PASCV
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
Microbix Engages with Diagnostics Industry Experts
Microbix Presenting at the 2026 Bloom Burton Conference
Critical Analysis: Immune Therapeutics (OTCMKTS:IMUN) & MBX Biosciences (NASDAQ:MBX)
MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know
MBX Biosciences, Inc. (NASDAQ:MBX) Given Average Recommendation of “Moderate Buy” by Brokerages
Microbix Biosystems Inc. (MBX:CA) Shareholder/Analyst Call Transcript
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
MBX Biosciences Appoints Karen Basbaum as Chief Business Officer
Microbix's Clot-Buster Drug Project Advances
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
MBX Biosciences to Participate in Upcoming March Investor Conferences
Microbix Biosystems Q1 Earnings Call Highlights
Microbix Biosystems Inc. (MBX:CA) Q1 2026 Earnings Call Transcript
Microbix Reports Results for Q1 2026
MBX Biosciences to Participate in Upcoming Investor Conferences
Microbix Biosystems (TSE:MBX) Share Price Passes Below 50-Day Moving Average – Time to Sell?
Microbix Presents Molecular Pathology Platform Results
Martin Marino Purchases 52,500 Shares of Microbix Biosystems (TSE:MBX) Stock
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair
MBX Biosciences, Inc. (MBX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
Microbix Biosystems (TSE:MBX) Shares Cross Below 50-Day Moving Average – Should You Sell?
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of “Moderate Buy” from Analysts
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High – Still a Buy?
Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6%
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference